Physician profile
Benjamin A Gonzalez
NPI 1457607269
$11,681.68
in general payments reported to CMS, 2019-2025
46 companies · $1,990 in 2025
The $1,990 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $1,667 · 2021: $2,154 · 2022: $1,655 · 2023: $1,673 · 2024: $1,302 · 2025: $1,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,965.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,674.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,652.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,248.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $726.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $622.08 | 2020-2025 | |
| Abbvie INC. | $615.06 | 2021-2025 | |
| Abbott Laboratories | $569.49 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $456.22 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.28 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $307.36 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $297.67 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $172.14 | 2019-2022 | |
| Inspire Medical Systems, INC. | $160.26 | 2025 | Inspire |
| Mayne Pharma Commercial LLC | $145.23 | 2021 | |
| Corcept Therapeutics | $143.91 | 2025 | Korlym |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.